<DOC>
	<DOCNO>NCT00003662</DOCNO>
	<brief_summary>RATIONALE : Umbilical cord blood transplantation may able replace cell destroy chemotherapy radiation therapy . PURPOSE : Phase II trial study effectiveness umbilical cord blood transplantation treat patient hematologic cancer hematologic metabolic disease .</brief_summary>
	<brief_title>Umbilical Cord Blood Transplantation Treating Patients With Hematologic Cancer Other Hematologic Metabolic Diseases</brief_title>
	<detailed_description>OBJECTIVES : I . Determine rate durable engraftment patient severe aplastic anemia , myelodysplastic syndrome , inborn error metabolism , inherit hematopoietic disorder refractory medical management , undergo high dose chemoradiotherapy follow unrelated cord blood ( UCB ) transplantation . II . Determine incidence severity acute chronic graft-versus-host disease patient . III . Monitor overall event-free survival patient . IV . Evaluate rate quality immunologic reconstitution patient . V. Determine whether nucleate cell progenitor cell content graft predictive engraftment . OUTLINE : This multicenter study . Patients stratify accord low v high weight . Patients severe aplastic anemia , myelodysplastic syndrome , bone marrow failure receive cyclophosphamide IV 1 hour day -6 -3 melphalan IV 20 minute day -4 -2 , antithymocyte globulin ( ATG ) IV 4 hour methylprednisolone IV 1 hour twice day day -3 -1 , total lymphoid irradiation day -1 . On day 0 , patient receive umbilical cord blood ( UCB ) infusion . Patients inborn error metabolism inherit hematopoietic disorder receive oral busulfan every 6 hour day -9 -6 , cyclophosphamide IV 1 hour day -5 -2 melphalan IV 20 minute day -4 -2 , ATG IV 4 hour methylprednisolone IV 1 hour day -3 -1 . On day 0 , patient receive UCB infusion . Patients Fanconi 's anemia receive ATG IV 4 hour methylprednisolone IV 1 hour day -6 -1 , cyclophosphamide IV 1 hour day -5 -2 , thoracoabdominal irradiation day -1 , UCB infusion day 0 . Patients also receive cyclosporine methylprednisolone begin day -2 continue necessary graft-versus-host disease prophylaxis . Patients follow indefinitely survival late toxicity . PROJECTED ACCRUAL : A total 4-90 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis one following : Severe aplastic anemia bone marrow cellularity le 20 % least 2 follow criterion : Granulocyte count le 500/mm3 Platelet count le 20,000/mm3 Reticulocyte count le 50,000/mm3 Etiologies may Fanconi 's anemia , hypoplastic leukemia , monosomy 7 , drug exposure ( chloramphenicol , NSAIDS ) , viral exposure ( EBV , hepatitis , parvovirus , HIV ) , nutritional deficiency , thymoma , paroxysmal nocturnal hemoglobinuria , amegakaryocytic thrombocytopenia Myelodysplastic syndrome ( MDS ) refractory medical management cytogenetic abnormality predictive transformation acute leukemia , include 5q , 7q , monosomy 7 , trisomy 8 De novo primary therapyrelated secondary MDS Refractory anemia refractory anemia ring sideroblast Inherited hematopoietic disorder refractory medical management Severe combine immunodeficiency Familial erythrophagocytic lymphohistiocytosis WiskottAldrich syndrome Kostmann 's syndrome ( infantile agranulocytosis ) Chronic granulomatous disease Leukocyte adhesion deficiency ChediakHigashi syndrome Paroxysmal nocturnal hemoglobinuria Fanconi 's anemia Dyskeratosis congenita DiamondBlackfan anemia Amegakaryocytic thrombocytopenia Osteopetrosis Gaucher 's disease LeschNyhan syndrome Mucopolysaccharidoses Lipidoses Must also meet following condition : No HLAABC/DR identical relate bone marrow UCB donor No 5/6 antigen match related bone marrow UCB donor Condition preclude wait search find donor National Marrow Donor Registry Must backup autologous haploidentical relate marrow Must available serologic match umbilical cord blood unit New York Blood Center 's Placental Blood Project PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 01 OR Karnofsky Lansky 80100 % Life expectancy : At least 3 month Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.0 mg/dL ALT/AST great 4 time normal Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 50 mL/min Cardiovascular : Shortening fraction ejection fraction least 80 % normal age Pulmonary : FVC FEV1 least 60 % predict age Adults : DLCO least 60 % predict Other : No active concurrent malignancy No active infection time backup bone marrow harvest pretransplant cytoreduction Not pregnant nursing Negative pregnancy test HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent cytotoxic chemotherapy Endocrine therapy : No concurrent immunosuppressive medication Radiotherapy : No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>noninvasive thymoma thymic carcinoma</keyword>
	<keyword>recurrent thymoma thymic carcinoma</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>